Cardio-vascular diseases are the main cause of death, emphasizing the need to improve patient treatment and survival. One therapeutic approach is a liposome-based drug carrier system specifically targeting constricted arteries. The recently discovered mechano-sensitive liposomes use hemodynamic shear-stress differences between healthy and constricted blood vessels as trigger for drug release. Liposomes are promising delivery containers but are being recognized as foreign by the immune system. Complement activation as essential factor of the recognition leads to adverse effects. Here, we tested complement activation by liposomes formulated from the artificial phospholipid Pad-PC-Pad in vitro. Surprisingly no complement activation was detected in human sera and porcine plasma. In in vivo experiments with three pigs, neither anaphylactic reactions nor other significant hemodynamic changes were observed even at comparably high liposome doses. The pilot study holds promise for an absence of complement-mediated adverse effects of Pad-PC-Pad liposomes in human.
According to the World Health Organization, cardiovascular diseases are responsible for 30% of worldwide deaths. 1 Many of them arise during transfer to hospital, motivating the increasing interest in pre-hospital drug delivery to critically constricted vessels. 2, 3 One strategy involves targeting the constricted arteries by capitalizing on the endogenous, elevated shear stresses present in diseased artery segments and using the changes as a purely physical trigger for drug release. 4 Liposomes composed of the artificial phospholipid Pad-PC-Pad can release their payload in areas of increased shear stress. 5 In order to push this development towards clinical application, the liposomes need to be further characterized to exclude non-desired systemic effects. Here, predicting the risk of complement-activationrelated-pseudo-allergy (CARPA) is fundamental, as it characterizes the hypersensitivity towards liposomal formulations. 6, 7 This phenomenon also occurs with clinically approved lipid-based drugs and creates adverse effects in 2% to 30% of people, occasionally leading to anaphylactic reaction or even death. 7, 8 Previous studies have shown that liposomal formulations including Doxil 9,10 and AmBisome 11 lead to lethal effects, if 0.5 to 5.0 mg/kg phospholipids are applied. First cell experiments with Pad-PC-Pad, however, have indicated a reasonable tolerance. 5 Therefore, we propose in vitro tests with human sera and porcine plasma to characterize the CARPA reaction and animal studies to search for liposome-induced blood-pressure Disclosure: The study was supported by the Swiss National Science Foundation within the project NO stress of the National Research Programme 62 Smart Materials. The authors report no conflicts of interest.
changes; both are fundamental to bridge the gap between bench and bedside. We hypothesize that contrary to Doxil and AmBisome the liposomes from the artificial phospholipid Pad-PC-Pad without an encapsulated active drug are reaction-free at comparable dose. Revealing such lack of complement activation, the native drug carrier could be assumed as safe from CARPA.
Methods
Pad-PC-Pad (1,3-palmitoylamido-1,3-deoxy-sn-glycero-2-phosphatidyl-choline) has been prepared according to the established protocol.
5 Figure 1 displays its structure in comparison to the natural 1,2-diesterphospholipid DPPC.
The liposomes were formulated using the thin-film method. 12 The phospholipids hydrated with PBS were extruded at a temperature between 65 and 70°C through 100 nm track-edged filters at a concentration of 20 mg/mL. The liposome stock suspension was stored without light at a temperature of 4°C. The experiments were conducted within 48 h after formulation. DLS measurements have shown no liposomes aggregation for in vitro testing, while their aggregation and sedimentation were observed after 12 h of storage in case of in vivo experiment (see Figure S1 ). Therefore, before bolus injection, the storage vial was repeatedly inverted to re-suspend the sediments, and, subsequently, the suspension was passed through a 0.22-μm syringe filter. the error bars, the liposomes do not induce any complement activation, whereas the complement activator zymosan triggered an immediate complement reaction more than 20 times higher than the negative control. The variability between the five donors is given in Figure S2 . The results are in line with placebo Doxil (Doxebo). 13 The soluble terminal complement complex SC5b-9 is formed from C5 to C9 as the end result of complement activation.
Results and discussion
14 An elevation of SC5b-9 against artificial phospholipid liposomes is therefore indicative for the in vivo reaction. Consequently, one does not expect in vivo reactions in pig experiments.
Indeed, Figure 3 demonstrates that the in vivo reactions have been consistent with the ELISA tests. Globally, the three pigs showed a stable hemodynamic behavior during anesthesia and after injection of Pad-PC-Pad. Since SAP, heart rate, and ECG were constant within the error bars, Figure 3 only displays PAP. Two pigs, Figure 3 , A and C, were injected with unfiltered, aggregated Pad-PC-Pad liposomal suspensions. The third pig, Figure 3 , B, was injected with a filtered, non-aggregated Pad-PC-Pad suspension. These injection regimens indicate the differences between homogeneous, equally sized liposomes and liposomal aggregates. The first pig (Figure 3, A1) showed no reaction after the 0.5 mg/kg injection. Even after the 5 mg/kg injection the PAP remains constant. Three minutes after an additional 5 mg/kg injection (Figure 3, A3) the PAP increased by 500 Pa (4 mmHg) for two minutes. The positive reference zymosan injection led to an immediate increase by more than 2.7 kPa (20 mmHg), long lasting reaction (Figure 3, A4) . The second pig showed no hemodynamic reaction applying doses of 0.5 and 5 mg/kg ( Figure 3 , B2 and B3, respectively). In the third pig (Figure 3, C) , the PAP was stable after the first aggregated liposome injection with a dose of 5 mg/kg, but increased by 930 Pa (7 mmHg) for a period of six minutes subsequent to the second injection. As the third pig was reactive to a certain extent, we decided to directly proceed with histological sampling and skip the zymosan injection. This histology analysis revealed that the administration of Pad-PC-Pad liposomes did not lead to histological toxic modification in kidney, lung, heart, and liver. Table 1 summarizes the analysis of the porcine blood. The values correspond to the ones reported for healthy Yorkshire pigs. 15 The lack of thromboxane changes in pigs is consistent with the in vitro test. C5a stimulates the production of arachidonic acid derivates prostaglandins and thromboxane by neutrophils and macrophages. The thromboxane levels remained stable during the entire experiment. They only increased following the zymosan injection.
To support the link between the in vitro and in vivo experiments complement activation was also measured via C3 consumption in pig plasma. The data, presented in Figure 4 , reveal the lack of complement activation.
Comparing the results of the in vivo study with data published on Doxil and AmBisome, we observed the lack of reactivity for Pad-PC-Pad liposomes. Even at one order of magnitude higher concentrations the non-aggregated Pad-PC-Pad liposomes do not trigger any reactivity in vivo. In conclusion, this pilot study was performed to explore the in vitro complement activation by Pad-PC-Pad and the in vivo CARPA reactivity in a pig model, which is more sensitive for CARPA than humans. The clinical relevance of the study lies in the increased risk for non-IGE-mediated reactions in patients treated for the first time with liposomal drugs. Although premedication reduces the risk of anaphylactic reactions, the risk for such reactions remains present. The findings indicate that Pad-PC-Pad liposomes do not directly or indirectly cause anaphylactic reactions even with a dose as high as 110 mg/kg. In comparison to approved phospholipid formulations, 7, 17 Pad-PC-Pad with a ten-or even hundred-fold higher dose reveals much less CARPA reactivity in vivo. To this end, Pad-PC-Pad is regarded as a promising phospholipid for liposomal drug delivery applications in humans. Figure S3 . The statistical analysis, as described for Figure 2 , demonstrates that the complement activation of the Pad-PC-Pad liposomes corresponds to the negative control.
